![Rank: 8](static/image/common/star_level3.gif) ![Rank: 8](static/image/common/star_level3.gif)
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
RS-1667
Viral hepatitis
Hepatitis B & D - clinical (Therapy, new compounds, resistance)
STOPPING TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AFTER LONG TERM VIROLOGIC SUPPRESSION IN HBEAG-NEGATIVE CHB: WEEK 48 INTERIM RESULTS FROM AN ONGOING RANDOMIZED, CONTROLLED TRIAL ("FINITE CHB")
Thomas Berg* 1, Karl-Georg Simon2, Stefan Mauss3, Eckart Schott4, Renate Heyne5, Dietmar Klass6, Christoph Eisenbach7, Tania M. Welzel8, Rainer Zachoval9, Gisela Felten10, Julian Schulze zur Wiesch11, Markus Cornberg12, Eduardo B. Martins13, Lothar Gallo13, Tobias Warger13, Jörg Petersen14
1Innere Medizin, Sektion Hepatologie, Universitätsklinikum, Leipzig, 2Gastroenterologische Gemeinschaftspraxis, Leverkusen, 3Zentrum HIV and Hepatogastroenterologie, Düsseldorf, 4Charite, 5Leberzentrum Checkpoint, Berlin, 6Innere Medizin I, Universitätsklinikum, Ulm, 7Universitätsklinikum, Heidelberg, 8J.W.-Goethe Universität, Frankfurt a. Main, 9Klinikum der LMU, München, 10Gastroenterologische Gemeinschaftspraxis, Herne, 11University Hamburg Eppendorf, Hamburg, 12Medizinische Hochschule, Hannover, Germany, 13Gilead Sciences, Foster City, United States, 14IFI Institut, Hamburg, Germany
Corresponding author’s email: lothar.***@****
Background and Aims: Long-term effective NUC therapy may lead to partial restoration of HBV-specific T cell functions. Stopping therapy in HBV-DNA suppressed HBeAg-negative patients may lead to initial viral rebound and hepatic flare followed by HBsAg clearance. We investigated HBsAg kinetics after controlled stopping of long-term TDF therapy.
Methods: Subjects on effective TDF therapy for at least 4 years were randomized to either stop or to continue TDF therapy for 144 weeks (advanced fibrosis/ cirrhosis excluded). Primary endpoint is HBsAg loss at Week 144. TDF could be restarted in case of clinically significant hepatitis B flares.
Results: 45 subjects were randomized in this open-label study at 13 sites in Germany (median age 45 years, 79% male, 88% Caucasian). 21 Stop-TDF subjects and 21 Continue-TDF subjects completed Week 48 (3 subjects withdrew consent– data excluded). At W48, Continue-TDF subjects maintained viral suppression, stable ALT, none lost HBsAg. 19 of 21 Stop-TDF subjects had early (first 12 weeks) substantial HBV DNA rebound (median 205,380 IU/mL, [Q1 59,995 IU/mL; Q3: 444,147 IU/mL]) accompanied by ALT elevations (median 106 IU/mL; [Q1 76 IU/ml; Q3 233 IU/mL]). 2 subjects had minimal HBV DNA rebound (max 259 IU/mL) and normal ALT; both had HBsAg levels <500 IU/ml at baseline (BL), while HBsAg levels in the other 19 subjects were substantially higher (median 52,640 IU/mL; [Q1 26,518 IU/mL; Q3 95,240 IU/mL; range 4,400 – 221,840 IU/mL]). At W48, 3 subjects had restarted TDF and all had returned to normal ALT and HBV DNA <LLQ, 18 subjects remained off TDF, 15/18 had normal ALT, 14/18 had HBV DNA 1 log (n=5, median -1.62 log) compared those with decline <1 log (n=13, median -0.23 log); median BL HBsAg levels were 14,888 IU/ml vs 52,280 IU/ml, respectively. Continue-TDF subjects had only small declines in HBsAg (median: -0.09 log).
Conclusions: Stopping TDF in chronic HBV HBeAg negative long-term suppressed subjects with defined restarting criteria appears to be safe and led to a significantly greater early HBsAg decline as compared to a continued TDF monotherapy. HBsAg loss was observed so far in two subjects (9.5%). If necessary, TDF can be effectively restarted. Lower HBsAg level at BL seems to be a predictive factor for HBsAg decline.
Disclosure of Interest: T. Berg: Grant: Gilead Sciences, Consultant: Gilead Sciences, Sponsored Lectures (National or International): Gilead Sciences, K.-G. Simon: Sponsored Lectures (National or International): Gilead Sciences, S. Mauss: Consultant: Gilead Sciences, Sponsored Lectures (National or International): Gilead Sciences, E. Schott: Consultant: Gilead Sciences, Sponsored Lectures (National or International): Gilead Sciences, R. Heyne: Grant: Gilead Sciences, D. Klass: Sponsored Lectures (National or International): Gilead Sciences, C. Eisenbach: : None Declared, T. Welzel: : None Declared, R. Zachoval: Consultant: Gilead Sciences, Sponsored Lectures (National or International): Gilead Sciences, G. Felten: : None Declared, J. Schulze zur Wiesch: Sponsored Lectures (National or International): Gilead Sciences, M. Cornberg: Grant: Gilead Sciences, Consultant: Gilead Sciences, Sponsored Lectures (National or International): Gilead Sciences, E. Martins: Employee: Gilead Sciences, L. Gallo: Employee: Gilead Sciences, T. Warger: Employee: Gilead Sciences, J. Petersen: Consultant: Gilead Sciences, Sponsored Lectures (National or International): Gilead Sciences
|
|